In addition, auspicious new drugs, including non-covalent Bruton tyrosine kinase inhibitors (BTKi) such as nemtabrutinib and pirtobrutinib, are in development with preliminary studies showing impressive efficacy in relapsed CLL after ibrutinib failure [10, 11]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.